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ORIGINAL ARTICLE
Helicobacter pylori–specific Protection Against Inﬂammatory
Bowel Disease Requires the NLRP3 Inﬂammasome and IL-18
Daniela B. Engler, PhD,* Irina Leonardi, MSc,† Mara L. Hartung, Msc,* Andreas Kyburz, MSc,*
Sabine Spath, PhD,‡ Burkhard Becher, PhD,‡ Gerhard Rogler, MD, PhD,† and Anne Müller, PhD*
Background: The Gram-negative bacterium Helicobacter pylori is a constituent of the human gastric microbiota. Chronic infection with H. pylori
causes gastritis and predisposes to gastric carcinoma but has also been inversely linked to various allergic and chronic inﬂammatory conditions. In
particular, large meta-analyses have documented an inverse association between H. pylori infection and the risk of developing ulcerative colitis and
Crohn’s disease.
Methods: We investigated possible protective effects of experimental H. pylori infection and of regular treatment with H. pylori extract in 2 mouse
models of colitis and in mouse models of type I diabetes and multiple sclerosis. The mechanism of protection was examined in mouse strains lacking
speciﬁc innate immune recognition pathways and cytokines.
Results: We show here that experimental infection with H. pylori and administration of regular doses of H. pylori extract both alleviate the clinical and
histopathological features of dextran sodium sulfate–induced chronic colitis and of T-cell transfer-induced colitis. High resolution endoscopy of the
protected animals revealed the accumulation of large amounts of colonic mucus upon H. pylori exposure, which could be attributed to transcriptional
activation of the mucin 2 gene. The protection against dextran sodium sulfate–induced colitis was dependent on the NLRP3 inﬂammasome and interleukin-
18 signaling. Other autoimmune diseases, i.e., experimental autoimmune encephalomyelitis and type I diabetes, were not controlled by H. pylori.
Conclusions: In summary, we propose here that the immunomodulatory activity of an ancient constituent of the gut microbiota, H. pylori, may be
exploited for the prevention and/or treatment of inﬂammatory bowel diseases.
(Inﬂamm Bowel Dis 2015;0:1–8)
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C rohn’s disease (CD) and ulcerative colitis (UC), collectivelyreferred to as inﬂammatory bowel diseases (IBDs), develop
in genetically susceptible individuals as the result of an inappro-
priately aggressive immune response to ubiquitous antigens of the
normal intestinal microﬂora. Genetic studies have highlighted the
importance of host–microbe interactions and of innate immune
recognition of components of the intestinal microbiota in the
pathogenesis of these chronic inﬂammatory disorders.1 The prev-
alence of both IBDs has increased in most developed countries
during the past century, a trend that has been attributed to changes
in diet, antibiotic use, and environmental factors and to changing
patterns of intestinal colonization.2 The biological hallmarks of
active inﬂammatory bowel disease are a pronounced inﬁltration of
innate and adaptive immune cells into the lamina propria and
elevated local levels of their cytokine products, especially tumor
necrosis factor-a, IL-1b, interferon (IFN)-g, and Th17 cell-
derived cytokines. Approved treatments for IBDs include amino-
salicylates or topical corticosteroids for mild disease forms and
systemic corticosteroids, immunosuppressive thiopurines, and bi-
ologics targeting tumor necrosis factor-a for moderately active or
severe disease courses or acute ﬂares.3 Alternative therapeutic
strategies in (pre) clinical development target cytokines involved
in IBD pathogenesis (IL-12 and IL-23), the a4b7 integrin
involved in lymphocyte homing to the gut, and JAK3 kinase,
which is involved in cytokine signaling.4 Additionally, rather
experimental strategies attempt to modulate pathogenic immune
responses in models of IBD by the introduction of helminths, such
as Heligmosomoides polygyrus5,6 or Trichuris suis7,8 or of pro-
biotics (especially Lactobacillus or Biﬁdobacterium species or the
Escherichia coli strain Nissle).9
Chronic gastric infection with the bacterial pathogen Heli-
cobacter pylori causes gastritis and peptic ulcer disease10 and
represents the most important risk factor for gastric cancer11,12
but has also been linked inversely to the risk of developing
allergic diseases and IBD in large epidemiological studies and
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meta-analyses.13–15 We have shown in various models that exper-
imental H. pylori infection prevents allergen-induced asthma by
inducing tolerogenic DCs, which acquire the ability to direct the
differentiation of protective FoxP3+ regulatory T cells.16–19 We
report here that experimental H. pylori infection and regular
administration of H. pylori extract protect against chronic colitis
in the dextran sodium sulfate (DSS) and T-cell transfer models of
the disease. Protective effects were evident during colonoscopy
and upon histological assessment of affected colonic tissues. Efﬁ-
cient protection from the chronic inﬂammation typical of DSS-
induced colitis required innate immune recognition of H. pylori
by the NLRP3 inﬂammasome and the subsequent production
and secretion of IL-18. NLRP32/2 as well as IL-182/2 and
IL-18R2/2 mice or mice lacking the downstream adaptor protein
MyD88, failed to respond to H. pylori extract treatment. The endos-
copy approach further revealed that H. pylori extract induced the
production of large quantities of protective mucus composed of the
intestinal mucin 2 (MUC2). Other autoimmune diseases, such as
type I diabetes (T1D), and experimental autoimmune encephalomy-
elitis were not controlled by H. pylori infection or H. pylori extract
administration. In summary, we provide evidence for the efﬁcacy of
a new treatment strategy for IBD that exploits the immunomodula-
tory properties of H. pylori, a naturally occurring infection known
to be inversely correlated with IBD risk in humans.
MATERIALS AND METHODS
Animal Experimentation
C57BL/6, BL/6.Nlrp32/2, BL/6.MyD882/2, BL/6.IL182/2,
and BL/6.IL18R2/2 mice were obtained from Jackson Laborato-
ries and maintained in individually ventilated cages under SPF
conditions. Eight-week-old mice were subjected to 3 cycles of 5
days each of 2% DSS followed by 1 week-long compound-free
intervals. To induce colitis in T-cell–deﬁcient hosts, BL/6.
TCRb2/2 mice (Jackson Labs) were intraperitoneally (i.p.) in-
jected with 400,000 naive CD4+CD62L+CD44lo T cells (puriﬁed
by immunomagnetic isolation, MagCellect Naive T cell kit;
R&D). Mice were either orally infected at 7 days of age with
108 H. pylori PMSS1 as described20 or received 3 weekly oral
or i.p. doses of 200 mg extract of H. pylori PMSS1 beginning after
the ﬁrst cycle of DSS treatment or on the day of T-cell transfer.
Colon length was measured from the cecum to the distal rectum;
colons were dissected longitudinally with one half being embed-
ded for formalin ﬁxation and parafﬁn embedding and the other
being cryopreserved for later RNA extraction. Parafﬁn sections
were stained with Giemsa and examined in blinded fashion on
a BX40 Olympus microscope. For induction of experimental
autoimmune encephalomyelitis (EAE), C57BL/6 mice were
immunized with 200 mg myelin oligodendrocyte glycoprotein
fragment 35-55 (MOG35-55) peptide adjuvanted by complete
Freund’s adjuvant, followed by two 200 ng i.p. injections of
pertussis toxin. Spontaneously developing type 1 diabetes was
assessed in female nonobese diabetic mice (NOD/ShiLtJ mice,
Jackson labs) at 20 weeks of age. For induction of T1D, male
NOD mice were i.p. injected with one 5 mg dose of cyclophos-
phamide at 10 weeks of age and assessed at 20 weeks of age. The
pancreas was formalin-ﬁxed and parafﬁn-embedded, and H&E-
stained sections were scored as described below. The inﬂamma-
tion of 30 pancreatic islets was recorded per animal. All animal
experimentation was performed in accordance with federal, can-
tonal, and institutional guidelines and was approved by the Zurich
Cantonal Veterinary Authorities.
Histopathological Analysis of Colitis, Insulitis,
and Gastritis, and Clinical Scoring of Colitis
and EAE
The scoring system ﬁrst introduced by Asseman et al21 was
used for the quantitative histopathological assessment of colitis.
A grade of 0 was given when no changes were observed; grade
1, minimal scattered mucosal inﬂammatory cell inﬁltrates, with or
without minimal epithelial hyperplasia; grade 2, mild scattered to
diffuse inﬂammatory cell inﬁltrates, sometimes extending into the
submucosa and associated with erosions, with minimal to mild
epithelial hyperplasia and minimal to mild mucin depletion from
goblet cells; grade 3, mild-to-moderate inﬂammatory cell inﬁl-
trates that were sometimes transmural, often associated with ulcer-
ation, with moderate epithelial hyperplasia and mucin depletion;
grade 4, marked inﬂammatory cell inﬁltrates that were often trans-
mural and associated with ulceration with marked epithelial
hyperplasia and mucin depletion; grade 5, marked transmural
inﬂammation with severe ulceration. Colitis endoscopy scores
were deﬁned for the following 5 parameters22: thickening of the
colon: 0, transparent; 1, moderate; 2, marked, 3, nontransparent;
changes of the vascular pattern: 0, normal; 1, moderate; 2,
marked; 3, bleeding; ﬁbrin visible: 0, none; 1, little; 2, marked;
3, extreme; granularity of the mucosal surface: 0, none; 1, mod-
erate; 2, marked; 3, extreme; stool consistency: 0, normal and
solid; 1, still shaped; 2, unshaped; 3, spread. Overall scores were
determined by adding all individual scores to reach 0 to 15. For
the daily clinical scoring of EAE, we used a previously published
procedure23 as follows: 0, no detectable signs of EAE; 0.5, distal
limp tail; 1, completely limp tail; 1.5, limp tail and hind limb
weakness; 2, unilateral partial hind limb paralysis; 2.5, bilateral
partial hind limb paralysis; 3, complete bilateral hind limb paral-
ysis; 3.5, complete bilateral hind limb paralysis and partial fore-
limb paralysis; 4, moribund (mouse completely paralyzed); 5,
dead. Food and water were provided in the cage after scores of
.1 were reached. H&E-stained sections of pancreas were scored
for insulitis based on a previously published system.24 Four
grades of insulitis were distinguished: grade 0, absence of insuli-
tis; 1, peri-insulitis; 2, light inﬁltration involving ,25% of the
islet area; 3, heavy inﬁltration involving .25% of the islet area.
The degree of H. pylori–induced gastritis/inﬂammation, atrophy,
and hyperplasia was scored on H&E-stained gastric sections
based on the modiﬁed “Sydney system,” as published previ-
ously.25 Brieﬂy, scores for chronic inﬂammation were 0, none;
1, some inﬁltrates; 2, mild (few aggregates in submucosa and
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mucosa); 3, moderate (several aggregates in submucosa and
mucosa); 4, marked (many big aggregates in submucosa and
mucosa); 5, nearly the entire mucosa contains a dense inﬁltrate;
and 6, entire mucosa contains a dense inﬁltrate. Scores for atrophy
were 0, none; 1, foci, where a few gastric glands are lost or
replaced; 2, small areas in which gastric glands have disappeared
or been replaced; 3, 25% of gastric glands lost or replaced; 4, 25%
to 50% of gastric glands lost or replaced; 5, 50% of gastric glands
lost or replaced; 6, only a few small areas of gastric differentiated
glands remaining. For hyperplasia, the scores were 0, none; 1,
single glands (next to inﬁltrate); 2, 1 focal area/1 to 4 crypts
(mild); 3, 1 to 3 foci; 4, multiple foci; 5, 50% of glands affected;
6, only few small nonhyperplasic areas.
Preparation of H. pylori Extract and
Quantiﬁcation of H. pylori Colonization by
Colony Count Assay
Helicobacter pylori was cultured in Brucella broth supple-
mented with 10% fetal calf serum, pelleted by centrifugation and
washed once with phosphate-buffered saline. Bacteria were sub-
jected to 3 freeze/thaw cycles and disrupted by 3 passes through
a French pressure cell press (Stansted Fluid Power, Cell Pressure
Homogenizer) at 30.000 bar. Cell debris was removed by centri-
fugation and the supernatant was ﬁltered through a 2-mm ﬁlter.
Protein concentrations were determined by BCA Protein Kit
(R&D systems). For the quantitative assessment of H. pylori col-
onization, one section of each stomach was transferred to a tube
containing Brucella broth and homogenized with an Ultra Turrax
homogenizer (John Morris Scientiﬁc Ltd., Chatswood, Australia).
Serial dilutions were plated on horse blood plates to determine
bacterial loads.
RNA Extraction, Reverse Transcription, and
Quantitative PCR
For real-time RT-PCR, total RNA was isolated from 1
longitudinal section of the colon using NucleoSpin RNA II kits
(Macherey-Nagel, Düren, Germany) and reversely transcribed using
SuperScript III Reverse Transcriptase (Life Technologies, Carlsbad,
CA). The corresponding cDNA served as a template for real-time
PCR performed using the LightCycler 480 SYBR Green I master kit
(Roche, Basel, Switzerland). Absolute values of MUC2, CDX-2,
TGF-b, IL-17, and IFN-g expression were normalized to GAPDH
expression (conditions: 608C annealing temperature, 50 cycles). The
following primers were used: GAPDH, forward: 50-GAC ATT
GTT GCC ATC AAC GAC C-30, reverse: 50-CCC GTT GAT
GAC CAG CTT CC-30; MUC2, forward: 50-TGCCCAGAGAG
TTTGGAGAG-30, reverse: 50-CCTCACATGTGGTCTGGTTG-30;
CDX-2, forward: 50-CTGGGGTTCTGAAACCAAAT-30, reverse:
50-CACCATCAGGAGGAAAAGTGA-30; TGFb, forward: 50-TG
ACGTCACTGGAGTTGTACGG-30, reverse: 50-GGTTCATG
TCATGGATGGTGC-30; IFNg, forward: 50-CATGGCTGTTT
CTGGCTGTTACTG-30; reverse: 50-GTTGCTGATGGCCTG
ATTGTCTTT-30, IL-17, forward: 50-GCTCCAGAAGGCCCT
CAG A-30; reverse: 50-AGCTTTCCCTCCGCATTGA-3.0
Statistics
All statistical analyses were performed using Graph Pad
prism 5.0 software (Graph Pad Software, San Diego, CA). The
Mann–Whitney test was used for all comparisons except for those
in EAE, where 2-way analysis of variance (ANOVA) was used to
determine signiﬁcant differences over time. P values ,0.05 were
considered signiﬁcant.
RESULTS
Live H. pylori and H. pylori Extract Protect
Effectively Against the Clinical and
Histopathological Features of Chronic Colitis
To assess whether experimental infection with H. pylori or
regular administration of H. pylori extract modulate the severity
of DSS-induced colitis, C57BL/6 mice were either experimen-
tally infected with 1 orogastric dose of the mouse-colonizing
H. pylori strain PMSS1 at 7 days of age or received intragastri-
cally administered H. pylori extract (10 mg/kg body weight) 3
times a week. All mice were exposed to three 5-day long cycles
of DSS in the drinking water (2% ﬁnal concentration), each fol-
lowed by a compound-free interval of 1 week. At the study
endpoint, mice were examined by high resolution colonoscopy
and assessed with respect to colonic histopathology and colon
length. Histopathological evaluation of the colon revealed that all
mice of the positive control group had developed moderate-to-
severe colitis, as evidenced by the widespread loss of goblet cells
and of crypts, accompanied by extensive mucosal and submuco-
sal inﬁltration of inﬂammatory cells (Fig. 1A, B). In contrast,
H. pylori–infected mice exhibited signiﬁcantly less inﬂammation
and had also undergone less substantial epithelial changes (Fig.
1A, B). Interestingly, a similar beneﬁcial effect was observed in
mice that were treated with H. pylori extract. Overall, signiﬁ-
cantly lower histopathology scores were assigned to the mice
in the 2 treatment arms exposed to live H. pylori or its extract
than to the positive controls (Fig. 1A, B). Lower histopathology
scores were associated with a decreased expression of the Th1
and Th17 cytokines IFN-g and IL-17 in the colonic mucosa of the
infected and treated mice (see Fig. A and B, Supplemental Digital
Content 1, http://links.lww.com/IBD/A714). An additional read-
out of colitis pathology known to correlate well with the histo-
pathological gold standard is colon length. Mice in the positive
control group exhibited substantially shorter colons than negative
controls that had never been exposed to DSS; H. pylori infection
or extract treatment restored normal colon length (Fig. 1C).
Finally, high resolution endoscopy22 was used to quantitatively
assess colitis in a subset of the mice shown in Figure 1A. Whereas
DSS-treated mice of the positive control group were characterized
by thickening and intransparency of the colon, mucosal bleeding,
abundant ﬁbrin, granularity of the mucosal surface, and loose
stools, all of these parameters were less severe in the H. pylori–
infected or extract-treated mice (Fig. 1D, E). Consequently, the
overall colonoscopy scores assigned on a scale from 0 to 1522 for
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the above-mentioned parameters were reduced from an average
of 10 (positive controls) to 5 (infected and extract treated; Fig.
1D). Interestingly, lower doses of extract (,10 mg/kg body
weight) or once-weekly treatment with the 10 mg/kg dose were
not sufﬁcient to confer protection (data not shown), whereas the
i.p. injection of H. pylori extract conferred a level of protection
that was quite similar to the protection provided by orogastric
delivery (Fig. 1A–E).
To determine whether the observed protective effects are
speciﬁc to the DSS model of barrier disruption followed by
microbiota-induced autoinﬂammation, we assessed the efﬁcacy of
extract treatment in the T-cell transfer-mediated model of colitis.26
Lymphopenic recipients of adoptively transferred naive CD4+ T
cells were either subjected to 3 times weekly treatment with
H. pylori extract or remained untreated. Whereas the recipients
of naive T cells in the positive control group developed severe
FIGURE 1. Helicobacter pylori infection and H. pylori extract treatment protect against DSS-induced colitis. C57BL/6 mice were either infected with
1 orogastric dose of live H. pylori (strain PMSS1) at 7 days of age or received 3 weekly doses of 200 mg H. pylori extract from the day of the ﬁrst DSS
cycle onwards, administered either i.p. or perorally (p.o.) and were subjected to three 5-day cycles of 2% DSS in the drinking water. A and B,
Histopathology scores and representative micrographs of Giemsa-stained tissue sections. Pooled data from 2 (inf., extr.i.p.) to 5 (pos. ctrl., extr.p.o.)
independent studies are shown. C, Colon lengths as determined from cecum to distal rectum for a subset of the mice shown in (A). D and E,
Colonoscopy scores and representative endoscopic images of a subset of the mice shown in (A). A, C, and D, Each data point represents 1 mouse;
horizontal lines indicate the medians. INF, infected; EXTR, extract-treated; POS CTRL, positive control; and NEG CTRL, negative control.
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colitis as determined by loss of body weight as well as histopath-
ological and endoscopical analysis, all symptoms were strongly
reduced in extract-treated animals (see Fig. C–E, Supplemental
Digital Content 1, http://links.lww.com/IBD/A714). All measured
parameters are thus consistent with protective effects of live
H. pylori infection and/or extract treatment on the development
of chronic colitis in 2 models of IBD. No adverse effects of the
extract treatment could be detected on the gastric mucosa of a non-
colitic control group (see Fig. F–G, Supplemental Digital Content
1, http://links.lww.com/IBD/A714), neither in the presence or
absence of an experimental H. pylori infection, indicating that
the treatment does not induce or aggravate H. pylori–associated
gastric pathology.
Helicobacter pylori Infection or Extract
Treatment Do not Ameliorate Experimental
Autoimmune Encephalomyelitis or Type
1 Diabetes
Hypothesizing that other autoinﬂammatory or autoimmune
conditions might also be prevented or ameliorated by H. pylori,
we examined the effects of H. pylori infection or extract treatment
in models of multiple sclerosis and T1D. To assess the effects of
H. pylori on multiple sclerosis–like autoimmune neuroinﬂamma-
tion, we immunized wild-type C57BL/6 mice with MOG35-55
peptide to trigger EAE. All mice developed central nervous sys-
tem inﬂammation as determined by scoring of the progressive
paralysis of tail and hind limbs within ;9 to 13 days postimmu-
nization; H. pylori infection or 3 times weekly treatment with
H. pylori extract did not measurably affect the course of disease
(Fig. 2A, B); if anything, extract treatment made the condition
worse. Similarly, H. pylori infection of female NOD mice, which
spontaneously develop pancreatic islet inﬂammation and repre-
sent a widely used model of T1D, did not result in improved
pancreatic histopathology (Fig. 2C, D). Finally, in a parallel
model of inducible T1D, male NOD mice were subjected to a sin-
gle dose of cyclophosphamide to trigger pancreatic islet inﬂam-
mation; as in the spontaneous model, neither live infection nor
extract treatment alleviated disease symptoms (Fig. 2E), suggest-
ing that T1D develops regardless of the presence of H. pylori. We
veriﬁed that H. pylori is fully competent to colonize NOD mice,
albeit at lower levels than the C57BL/6 mice used in the DSS-
induced colitis model (Fig. 2F). In conclusion, our results indicate
that prototypical autoimmune diseases are not controlled by live
H. pylori and therefore also fail to respond to H. pylori extract
treatment.
Protection Against Colitis Conferred by Live
H. pylori or Its Extract Is Accompanied by
MUC2 Upregulation and Depends on the
NLRP3 Inﬂammasome and IL-18 Signaling
The most striking endoscopic feature of mice that are
protected against experimentally induced colitis by either live
H. pylori infection or extract treatment is their abundant mucus
production (Fig. 1E). The predominant intestinal mucin, MUC2,
is produced by goblet cells and forms an insoluble barrier that
protects the intestinal epithelium against colonization by gut mi-
crobes.27 We investigated the expression of MUC2 transcript and,
in accordance with the endoscopy results, found it to be strongly
upregulated in the intestinal mucosa of H. pylori–infected and
extract-treated mice relative to colitic controls (Fig. 3A). The
intestinal transcription factor CDX2, which regulates MUC2 pro-
duction,28 is upregulated in a similar manner in the protected mice
(Fig. 3B). Having identiﬁed a copy of the SMAD binding motif
CAGACA29 in the CDX2 promoter sequence, we speculated that
the regulatory cytokine TGF-b, known to be critically involved in
H. pylori–speciﬁc immunomodulation and in intestinal homeosta-
sis,20,30 might play a role in H. pylori–induced colitis protection.
The expression pattern of TGF-b indeed paralleled those of
MUC2 and CDX2 (Fig. 3C), suggesting that the TGF-b-CDX2-
MUC2 axis represents a strong correlation of, or is functionally
involved in, colitis protection. To examine whether MUC2
induction by H. pylori extract is a phenomenon linked to DSS
treatment, we treated a large group of mice with 3 times weekly
doses of H. pylori extract without exposing them to DSS at
any time; this treatment recapitulated the strong MUC2 induction
seen in DSS-treated mice (Fig. 3D), indicating that intestinal
MUC2 upregulation is a direct result of the exposure to H. pylori
extract rather than a consequence of the protection from DSS
colitis.
We and others have reported recently that H. pylori acti-
vates the inﬂammasome and caspase-1 to induce the processing
and secretion of IL-1b and IL-18.31,32 IL-18 signaling is required
for the protection against allergic asthma that is conferred by live
infection17 and H. pylori extract treatment.18 Several polymor-
phisms in the IL-18 gene are known to contribute to UC suscep-
tibility.33 To test whether a functional NLRP3 inﬂammasome, the
predominant inﬂammasome detecting H. pylori,32 and IL-18 sig-
naling proﬁciency are required for H. pylori extract-mediated pro-
tection, we subjected mice lacking NLRP3, IL-18, IL-18 receptor,
or the adaptor protein MyD88 to DSS-induced colitis and treated
the mice with H. pylori extract. None of these strains were pro-
tected against DSS-induced colitis, despite the fact that wild-type
mice examined in the same experiment exhibited a typical level of
protection (Fig. 3E). The activation of the NLRP3 inﬂammasome
and subsequent secretion of IL-18 upon extract treatment thus are
important prerequisites of H. pylori extract–mediated colitis
protection.
DISCUSSION
The combined results presented here demonstrate that
H. pylori, administered either live or in extract form, confers pro-
tection against IBD in standard mouse models of the disease. Our
data are consistent with a strong inverse correlation of H. pylori
seropositivity with the risk of developing both CD and UC,13,15 as
well as with experimental data documenting a protective effect of
live H. pylori infection on acute Salmonella typhimurium–induced
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typhlocolitis.34 The enteroprotective effects of H. pylori in the
latter model have been attributed to immunoregulatory sequences
in the genomic DNA of H. pylori, which downregulate proinﬂam-
matory cytokine production and induce tolerogenic properties in
dendritic cells.35 Here, we ﬁnd that the H. pylori–speciﬁc
activation of the NLRP3 inﬂammasome and the subsequent pro-
cessing and secretion of mature IL-18 are critical events in colitis
protection. We and others have shown earlier that H. pylori efﬁ-
ciently activates the (NLRP3) inﬂammasome in innate immune
cells to induce the autoproteolytic cleavage of caspase-1 and
FIGURE 2. Helicobacter pylori infection and H. pylori extract treatment fail to protect against EAE and T1D. A and B, C57BL/6 mice were either
infected on day 7 of age with H. pylori (16 mice) or received 3 weekly i.p. doses of 200 mg H. pylori extract from day 7 of age onwards (12 mice), or
remained untreated (24 mice). All mice were immunized with MOG35-55 peptide at 6 weeks of age and monitored for EAE symptoms for 19 days
thereafter. Averages 6 SDs of EAE scores of the 3 treatment groups are shown in (A). Colony-forming units per stomach as determined by plating
and colony counting are shown in (B) for all infected mice. Pooled data from 2 independent studies are shown in (A) and (B). C and D, Female NOD
mice were either infected on day 7 of age with H. pylori (18 animals) or remained uninfected (17 animals) and were killed at 20 weeks of age for
the histopathological assessment of spontaneously occurring insulitis. Four nondiabetic NOD/SCID mice were included as negative controls.
Histopathology scores are shown in (C) along with representative micrographs of the NOD groups in (D). E and F, Male NOD mice were either
infected on day 7 of age with H. pylori (8 mice) or received 3 weekly i.p. doses of 200 mg H. pylori extract from day 7 of age onwards (3 mice) or
remained untreated (14 mice). All mice except for 4 negative controls received 1 i.p. dose of 5 mg cyclophosphamide at 10 weeks of age and were
assessed histopathologically at 20 weeks of age. Histopathology scores and colony-forming units, relative to age-matched C57BL/6 mice, are
shown in (E) and (F). inf., infected; extr., extract-treated; pos. ctrl., positive control; neg. ctrl., negative control.
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the processing of pro-IL-1b and pro-IL-18 into the mature cyto-
kines.31,32,36 Interestingly, the 2 caspase-1 substrates fulﬁll very
different, even opposing, functions in the H. pylori/host interac-
tion. Whereas IL-1b has a strong pro-inﬂammatory role, promot-
ing the differentiation of H. pylori–speciﬁc Th1 and Th17 cells
and immune control of H. pylori on the one hand and infection-
associated gastric immunopathology on the other,31,32 the net
effect of IL-18 signaling in the context of H. pylori infections is
anti-inﬂammatory rather than pro-inﬂammatory. Expression of
IL-18 and signaling through its receptor is dispensable for
H. pylori infection control; in fact, mice that lack either the ligand
or the receptor are capable of controlling H. pylori loads more
efﬁciently because of their unrestricted H. pylori–speciﬁc Th17
responses.17,31 As another consequence of excessive gastric
Th17 activation, IL-182/2 and IL-18R2/2 mice develop severe
infection-associated immunopathology.31 Helicobacter pylori–
induced IL-18 is not only required for the prevention of immu-
nopathology and for the protection against IBDs as shown here
but has also emerged as a critical factor in H. pylori–induced
asthma prevention.17,18 In asthma, IL-18, which is secreted in
large amounts by DCs that have been exposed to H. pylori
in vitro or in vivo, promotes the differentiation of naive T cells
into FoxP3+CD25+ regulatory T cells with highly suppressive
activity.17 CD4+CD25+ T cells isolated from the mesenteric
lymph nodes of wild type, but not IL-182/2 and IL-18R2/2
donors, confer asthma protection to naive recipients.17 Whether
IL-18–mediated protection in the colitis model depends simi-
larly on the induction and function of Tregs remains to be
determined. In the gut, an alternative IL-18–dependent sce-
nario can be envisioned that involves the production of large
amounts of intestinal mucins, which are known to protect
against colitis.37 Our observation that MUC2 mucus produc-
tion is induced by live H. pylori and extract, and correlates
well with protection, is reminiscent of a recently described
innate immune mechanism linking the microbiota-induced
activation of the NLRP6 inﬂammasome to goblet cell mucus
hypersecretion.37 Whereas NLRP6-dependent mucus produc-
tion was attributed to mucin granule exocytosis37 rather than
transcriptional activation of MUC2 gene expression as dem-
onstrated here, the net effect of enhanced protective mucus
production is comparable in both scenarios. In conclusion,
we propose here that the activation of mucus production
through the NLRP3/caspase-1/IL-18 axis by H. pylori extract
or live bacteria forms the mechanistic basis for a possible new
treatment modality for IBD that is projected to be safe and
cost-effective and exploits the immunomodulatory properties
of a naturally occurring infectious agent known to be inversely
associated with IBD risk in human populations.
FIGURE 3. Helicobacter pylori infection and extract treatment induces MUC2 expression and confers protection against DSS colitis in a NLRP3-
dependent and IL-18–dependent manner. A–C, C57BL/6 mice were treated as described in Figure 1. Colonic mucosal tissue was subjected to RNA
extraction and qRT-PCR for MUC2, CDX2, and TGF-b transcripts; expression levels were normalized to GAPDH. D, 6-week-old mice that had been
treated 3 times weekly with 200 mg H. pylori extract from day 7 of age onwards were subjected to MUC2 qRT-PCR, normalized to GAPDH. No DSS
was administered to these mice. E, Mice of the indicated genotypes were treated with H. pylori extract as described in Figure 1 and exposed to 3
cycles of DSS in the drinking water. Pooled histopathology scores of 3 independent studies are shown.
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